The gastrointestinal tract and glucose tolerance

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 7, Issue 4, 2004, Pages 479-484

  Vella, Adrian ^a   Camilleri, Michael ^a   Rizza, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Gastric emptying; Glucose intolerance; Incretin

Indexed keywords

ADENYLATE KINASE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; GLUCAGON; INSULIN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

DIABETES MELLITUS; FOOD INTAKE; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MEDICAL INFORMATION; NONHUMAN; REVIEW; SATIETY; STOMACH EMPTYING; ENERGY METABOLISM; HOMEOSTASIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; SECRETION;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 12244296648     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mco.0000134375.01310.97     Document Type: Review

References (55)

1. Basu A, Alzaid A, Dinneen S, et al. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 1996; 97:2351-2361.
2. Bantle JP, Laine DC, Castle GW, et al. Postprandial glucose and insulin responses to meals containing different carbohydrates in normal and diabetic subjects. N Engl J Med 1983; 309:7-12.
3. Basu A, Caumo A, Bettini F, et al. Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. Diabetes 1997; 46:421-432.
4. Ferrannini E, Simonson DC, Katz LD, et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 1988; 37:79-85.
5. Firth RG, Bell PM, Marsh HM, et al. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. J Clin Invest 1986; 77:1525-1532.
6. Nauck MA, Meier JJ, Creutzfeldt W. Incretins and their analogues as new antidiabetic drugs. Drug News Perspect 2003; 16:413-422. Outline of the therapeutic potential of incretins and their analogues.
7. Vella A, Shah P, Basu R, et al. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000; 49:611-617.
8. 2 on glucose metabolism.
9. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994; 93:2263-2266.
10. Basu A, Rizza RA. Glucose effectiveness: measurement in diabetic and nondiabetic humans. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2):S157-S165.
11. Sandhu H, Wiesenthal SR, MacDonald PE, et al. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 1999; 48:1045-1053.
12. Vella A, Shah P, Basu R, et al. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes 2001; 50:565-572.
13. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, et al. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 1994; 37:1163-1166.
14. Merida E, Delgado E, Molina LM, et al. Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 1993; 77:1654-1657.
15. Villanueva-Penacarrillo ML, Delgado E, Trapote MA, et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 1995; 146:183-189.
16. Morales M, Lopez-Delgado MI, Alcantara A, et al. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997; 46:1264-1269.
17. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318:429-435.
18. Montrose-Rafizadeh C, Yang H, Rodgers BD, et al. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 1997; 272:21201-21206.
19. Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998; 19:877-882.
20. Deacon CF, Plamboeck A, Moller S, Holst JJ. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002; 282:E873-E879.
21. Vella A, Shah P, Reed AS, et al. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002; 45:1410-1415.
22. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:707-713.
23. Frank JW, Saslow SB, Camilleri M, et al. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109:755-765.
24. Gonlachanavit S, Hsu CW, Boden GH, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci 2003; 48:488-497. Effectively illustrates the importance of the rate of gastric emptying in the maintenance of glucose tolerance.
25. Chandalia M, Garg A, Lutjohann D, et al. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000; 342:1392-1398.
26. Russo A, Stevens JE, Wilson T, et al. Guar attenuates fall in postprandial blood pressure and slows gastric emptying of oral glucose in type 2 diabetes. Dig Dis Sci 2003; 48:1221-1229. Illustrates the effect of guar on gastric emptying in glucose tolerance.
27. Li J, Kaneko T, Qin LQ, et al. Long-term effects of high dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: comparison among barley, rice, and cornstarch. Metabolism 2003; 52:1206-1210. Experimental evidence to support the beneficial effects of high dietary fiber.
28. Kriketos AD, Sam W, Schubert T, et al. Postprandial triglycerides in response to high fat: role of dietary carbohydrate. Eur J Clin Invest 2003; 33:383-389. Demonstrates that by stimulating insulin secretion, the addition of carbohydrate to fat can dampen postprandial lipidemia.
29. Todd JF, Edwards CM, Ghatei MA, et al. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Lond) 1998; 95:325-329.
30. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:2719-2725. Proof that continuous intravenous GLP-1 can delay gastric emptying, suppress glucagon, and increase insulin secretion to improve glucose tolerance in patients with type 2 diabetes.
31. Thumshirn M, Camilleri M, Choi MG, Zinsmeister AR. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology 1999; 116:573-585.
32. Gilja OH, Hausken T, Wilhelmsen I, Berstad A. Impaired accommodation of proximal stomach to a meal in functional dyspepsia. Dig Dis Sci 1996; 41:689-696.
33. Wettergren A, Petersen H, Orskov C, et al. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994; 29:501-505.
34. Schirra J, Kuwert P, Wank U, et al. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 1997; 109:84-97.
35. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282:G424-G431.
36. Delgado-Aros S, Vella A, Camilleri M, et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil 2003; 15:435-443. Examination of the effects of GLP-1 on gastric function in the presence of autonomic neuropathy.
37. Stadaas JO. Gastric motility 1 year after proximal gastric vagotomy. Scand J Gastroenterol 1980; 15:799-804.
38. Hartley MN, Mackie CR. Gastric adaptive relaxation and symptoms after vagotomy. Br J Surg 1991; 78:24-27.
39. Hwang JH, Perseghin G, Rothman DL, et al. Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 1995; 95:783-787.
40. Cline GW, Rothman DL, Magnusson I, et al. 13C-nuclear magnetic resonance spectroscopy studies of hepatic glucose metabolism in normal subjects and subjects with insulin-dependent diabetes mellitus. J Clin Invest 1994; 94:2369-2376.
41. Vella A, Shah P, Basu R, et al. Type I diabetes mellitus does not alter initial splanchnic glucose extraction or hepatic UDP-glucose flux during enteral glucose administration. Diabetologia 2001; 44:729-737.
42. Damci T, Nuhoglu I, Devranoglu G, et al. Increased intestinal permeability as a cause of fluctuating postprandial blood glucose levels in Type 1 diabetic patients. Eur J Clin Invest 2003; 33:397-401. Interesting observation of increased intestinal permeability in type 1 diabetes that merits further investigation.
43. Pencek RR, Koyama Y, Lacy DB, et al. Prior exercise enhances passive absorption of intraduodenal glucose. J Appl Physiol 2003; 95:1132-1138. Mechanistic investigation of the effect of exercise on glucose tolerance.
44. Hamilton KS, Gibbons FK, Bracy DP, et al. Effect of prior exercise on the partitioning of an intestinal glucose load between splanchnic bed and skeletal muscle. J Clin Invest 1996; 98:125-135.
45. Pagliassotti MJ, Myers SR, Moore MC, et al. Magnitude of negative arterial-portal glucose gradient alters net hepatic glucose balance in conscious dogs. Diabetes 1991; 40:1659-1668.
46. Smith D, Pernet A, Reid H, et al. The role of hepatic portal glucose sensing in modulating responses to hypoglycaemia in man. Diabetologia 2002; 45:1416-1424.
47. Ishida T, Chap Z, Chou J, et al. Differential effects of oral, peripheral intravenous, and intraportal glucose on hepatic glucose uptake and insulin and glucagon extraction in conscious dogs. J Clin Invest 1983; 72:590-601.
48. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001; 50:1720-1728.
49. Zangeneh F, Basu R, Shah P, et al. Enteral infusion of glucose at rates approximating EGP enhances glucose disposal but does not cause hypoglycemia. Am J Physiol Endocrinol Metab 2003; 285:E280-E286. Demonstration that enteral glucose feeding does not cause hypoglycemia in humans but may enhance peripheral glucose disposal.
50. Vella A, Shah P, Basu R, et al. Effect of enteral vs. parenteral glucose delivery on initial splanchnic glucose uptake in nondiabetic humans. Am J Physiol Endocrinol Metab 2002; 283:E259-E266.
51. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
52. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1-F8.
53. Woerle HJ, Mariuz PR, Meyer C, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52:918-925. Mechanistic study of worsening glucose tolerance associated with protease inhibitors.
54. Basu R, Di Camillo B, Toffolo G, Basu A, Shah P, Vella A, Rizza R, Cobelli C. Use of a novel triple-tracer approach to assess postprandial glucose metabolism. Am J Physiol Endocrinol Metab 2003; 284:E55-E69. Promising new methodology to measure and model glucose metabolism, avoiding the limitations of the minimal model.
55. Basu R, Breda E, Oberg AL, et al. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003; 52:1738-1748. Mechanistic study of the mechanisms by which aging contributes to glucose intolerance.